Your Go-To Laboratory CRO for global Analytical Services in Clinical Trials and Vaccine Development
The global network of Eurofins Central Laboratory companies is dedicated to providing End-to-End clinical laboratory testing solutions. With our 4 standardized, wholly-owned testing sites in the US, the Netherlands, Singapore, and China, we provide CAP/CLIA certified analytical services in both a GCP and GCLP environment. This allows us to combine safety and efficacy analysis with Biomarker Services embedded within one laboratory, introducing cost efficiencies into Sponsor study budgets, and increasing specimen integrity by reducing unnecessary transport.
Reliable, high-quality laboratory data is pivotal to the success of clinical trials. It’s the RESULTS THAT MATTER. Since laboratory testing is the sole focus of our companies, we go above and beyond to provide a myriad of services to ensure that any clinical trial sample is collected, transported, managed, analyzed, reported, and stored to meet the objectives and purpose of each study. We are dedicated to providing the most cost-effective and efficient solutions to pharmaceutical and biotech companies, and CROs alike.
What differentiates our network from the rest? Innovation. Whether that is our specimen visibility tool, EzRF (web-based requisition), our home-based, virtual trial patient specimen collection kits, or our traveling laboratory technician service for standardized CAP certified on-site analysis of rapid analytical TAT requirements (PBMC, semen analysis, virology specimen processing), the Eurofins Central Laboratory companies are your analytical solution for Phase 1 to 4 clinical trials.
With Eurofins Central Laboratory acting as the hub, in a hub and spoke model, our Clients will have access to all specialized companies within the Eurofins BioPharma Services network. This includes Eurofins companies focusing on Oncology and Pathology, Genomics, Virology and Immunology, Bioanalytical Services, Early Clinical Development Services, and the Eurofins In support of full service, central laboratory contracts, Optimed Phase 1 unit. Clients will be provided access to all these units of specialization with single-source contracting and invoicing.
CENTRAL LAB
The Evolution of the Central Laboratory Network
As part of the Eurofins BioPharma Services companies, the Eurofins Central Laboratory network has amassed more than 25 years of experience. Our clients benefit from the fact that we belong to one of the world’s leading laboratory testing organizations since 2001. This means you’ll enjoy end-to-end testing solutions, free from the worry of coordinating multiple vendors. Our testing capabilities are unsurpassed and we are setting new standards with our GCLP capabilities embedded within the Central Laboratory.
Come on, give us a try…
OUR HISTORY
In 1987, Eurofins was founded when Gilles Martin, the current Group CEO, purchased the rights to the ground-breaking testing technology SNIF-NMR® from the University of Nantes. It uses Nuclear Magnetic Resonance to detect whether sugar has been added during the wine-making process to increase the alcohol content. Certain such additions were not detectable by any other existing method. In the following years, the SNIF-NMR® technology applications were broadened to a wider range of products than the original wine test, such as fruit juices, natural flavors, and other nonalcoholic beverages, picking up sophisticated frauds that traditional testing methods failed to detect.
In 2020, as the Covid-19 pandemic hit the world, within just two months Eurofins laboratories developed a complete range of PCR tests to detect SARS-CoV-2 and serology tests to detect antibodies, as well as multiple programs to support the biopharmaceutical industry in the development of new vaccines, drugs, and medical products to fight the virus.
By 2022, the Group has grown to 58,000 staff across a network of 900 laboratories in 54 countries, offering a portfolio of over 200,000 analytical methods. Having completed the building of a best-in-class global laboratory infrastructure and having achieved significant global scale as a result of its massive 2015-2020 expansion program, Eurofins is now planning to leverage its unique position in a new phase of its development, with a particular focus on operational excellence and innovation.